Always Evolving and Adapting

Shareholder Approvals, Disclosure & Governance

Strategic legal counsel regarding shareholder approvals and governance in M&A. Expert guidance on SEC proxy rules, investor communications, and equity-related items for domestic and international transactions.

In any transformative M&A transaction, the bridge between a Board’s strategic vision and the final execution is the shareholder approval process. At Anthony, Linder & Cacomanolis, we serve as the lead partner in architecting this phase, confirming that the governance framework and disclosure strategy are managed with the precision required to facilitate a successful vote. Our “deal-maker” philosophy dictates that we anticipate stockholder concerns and regulatory friction early, turning complex proxy requirements into a structured path toward transaction closure.

The Statutory and Exchange-Based Approval Framework

The requirement for shareholder approval is driven by both state corporate law—such as the Florida Business Corporation Act or the Delaware General Corporation Law (DGCL)—and national exchange listing standards. For transactions involving the issuance of 20% or more of a company’s outstanding common stock or voting power, Nasdaq and NYSE rules mandate a formal stockholder vote.

Anthony, Linder & Cacomanolis provides the sophisticated counsel required to determine when a vote is triggered, whether for a direct merger, a significant asset sale, or a change of control.

SEC Proxy Rules and Disclosure Mandates

For public companies, the shareholder approval process is governed by the rigorous disclosure requirements of Regulation 14A and Schedule 14A. We lead the preparation of the proxy statement, architecting a document that provides the “white-label” compliant transparency necessary to secure SEC clearance and institutional support.

Our firm dictates a proactive approach to the disclosure of “background of the merger” sections, fairness opinions, and financial projections. We manage the SEC comment process with authoritative precision, confirming that the definitive proxy statement is distributed within the strategic timeline of the deal.

Investor Communications and Regulation FD

The period between deal announcement and the shareholder vote is a critical window for investor relations. Anthony, Linder & Cacomanolis guides the C-suite through the nuances of Regulation FD (Fair Disclosure) to confirm that communications with analysts and institutional holders do not result in selective disclosure violations.

We architect the “deal-maker” communication strategy, reviewing press releases, investor presentations, and social media content to facilitate a consistent and compliant narrative. By managing the filing of these communications as “proxy soliciting material” under Rule 14a-12, we confirm that the company maintains its regulatory integrity while actively engaging with its stockholder base to secure the necessary affirmative votes.

Equity-Related Items and Appraisal Rights

M&A transactions often trigger complex equity-related considerations, including the treatment of outstanding warrants, options, and restricted stock units. Our firm guides clients through the precise legal architecture for the assumption or cancellation of these instruments, confirming that the cap table remains accurate and compliant through the closing date.

Furthermore, we advise on the management of appraisal rights or “dissenters’ rights,” where shareholders may seek a judicial determination of the fair value of their shares.

Strategic Consultation and Governance Execution

The management of shareholder approvals and governance requires a lead partner who understands that transparency is a tool for deal closure. We invite CEOs, CFOs, and Boards of Directors to engage in a high-level consultation to evaluate the governance and disclosure architecture of your next transaction.

For immediate assistance or to schedule a strategy consultation regarding shareholder approvals and M&A governance, please contact our South Florida headquarters by calling 877-541-3263 or visiting our contact page.